Grant: Engage Grants Program
University of British Columbia
$25,000.00
Engineering a novel protein with cryogenic organ protective activity
EF 2010-11
Résumé
Solid organ transplantation is an effective treatment option for patients with end-stage organ disease and often
becomes the only solution for these patients.
One of the most important factors determining the organ transplantation success is the management of donor
organ preservation. Usually, donor organs are stored/ transported in cold temperature to increase their shelf life.
However, the cold temperature damages the organ via ischemic shock. The longer the organ is stored in
cryogenic condition, the higher the risk it is at for delayed graft function, transplanted graft rejection and
ultimately decreasing patient survival as more and more of the organ's cells die via cold temperature induced
necrosis. In addition, the subsequent rewarming of the organ and reperfusion of warm blood can damage the
organ even further as the temperature shock causes even more of the cells in the organs to die via apoptosis.
Clusterin (CLU) is a novel, cell protective protein that may be able to solve both of these problems. There
are enough past experimental evidences to support that CLU can both 1) protect the cells in cold temperature,
preventing necrosis and cell death, and 2) inhibit apoptotic cell death resulting from the temperature shock
during the rewarming of the organ. However, in order for CLU to have these functions on the protection of
cells/organs in donor organ preservation, CLU needs to be re-engineered biochemically so that it can penetrate
the cell's outer membrane and enter the inside of cell before cell death occurs.
Through collaborative research, we plan to study the impact of various biochemical and sequence
modifications of CLU on its ability to penetrate cells and affect the viability of cells during and after cryogenic
storage. The experimental from this research will allow us develop a novel technology in managing organ
preservation and ultimately save the lives of patients undergoing organ transplantation.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
396341-2010
Name nom
Du, Caigan
Department département
Urologic Sciences
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2010
Competition year année de concours
2010
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
1
Nb partie
1
Application title
Engineering a novel protein with cryogenic organ protective activity
Keyword
NSERC
Application summary
Solid organ transplantation is an effective treatment option for patients with end-stage organ disease and often
becomes the only solution for these patients.
One of the most important factors determining the organ transplantation success is the management of donor
organ preservation. Usually, donor organs are stored/ transported in cold temperature to increase their shelf life.
However, the cold temperature damages the organ via ischemic shock. The longer the organ is stored in
cryogenic condition, the higher the risk it is at for delayed graft function, transplanted graft rejection and
ultimately decreasing patient survival as more and more of the organ's cells die via cold temperature induced
necrosis. In addition, the subsequent rewarming of the organ and reperfusion of warm blood can damage the
organ even further as the temperature shock causes even more of the cells in the organs to die via apoptosis.
Clusterin (CLU) is a novel, cell protective protein that may be able to solve both of these problems. There
are enough past experimental evidences to support that CLU can both 1) protect the cells in cold temperature,
preventing necrosis and cell death, and 2) inhibit apoptotic cell death resulting from the temperature shock
during the rewarming of the organ. However, in order for CLU to have these functions on the protection of
cells/organs in donor organ preservation, CLU needs to be re-engineered biochemically so that it can penetrate
the cell's outer membrane and enter the inside of cell before cell death occurs.
Through collaborative research, we plan to study the impact of various biochemical and sequence
modifications of CLU on its ability to penetrate cells and affect the viability of cells during and after cryogenic
storage. The experimental from this research will allow us develop a novel technology in managing organ
preservation and ultimately save the lives of patients undergoing organ transplantation.